EVOTEC SE INH O.N.
Commented by André Will-Laudien on September 25th, 2024 | 07:00 CEST
The biotech rally of the century is on the horizon! 150% returns with BioNTech, Pfizer, Nyxoah, Bayer, or Evotec?
The stock market keeps climbing, and now it is moving even faster with a double-whammy interest rate cut from the Fed! In a surprising move, the US Federal Reserve pulls a 0.5% rate cut from its magic hat, boosting market sentiment. Now, it is certain that life will continue in the biotech sector. However, selecting the right stocks remains challenging. With a medium-term focus, paying attention to management quality is important because the recent price declines were too high in some cases. However, some research approaches promise a better future. BioNTech, Pfizer, and Bayer have already bottomed out. Nyxoah and Evotec are now showing the first signs of breaking out after a period of consolidation. What is the short-term outlook?
Read
Commented by André Will-Laudien on September 18th, 2024 | 07:30 CEST
Turnaround stocks – Here we go! 250% returns with thyssenkrupp, nucera, Evotec, VCI Global and A2Z Cust2Mate
The stock markets are going up and up, even in the most challenging stock market month of the year. Because the market had already corrected in July, the bulls say that the need to catch up is all the greater due to upcoming interest rate cuts by central banks. The bears believe that the valuation of tech and AI stocks, in particular, is already far too advanced and are hoping for a correction. Yet, green signals dominate daily, and now the question is which lagging stocks to invest in. Of course, it does not work without fundamentals, but sometimes insider buying is enough to lift sentiment. We select promising risk-return profiles for risk-conscious investors.
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by Fabian Lorenz on September 5th, 2024 | 09:15 CEST
Bargain alert in Biotech, AI, Cannabis: Evotec, Cantourage, BlockchainK2 share instead of Nvidia?
The weak late summer months on the stock market often offer opportunities for bargain hunters - including at the moment and away from the large caps. For instance, Nvidia has already lost around 30% from its all-time high, but historically a drop of 50% or more is not uncommon for this AI high-flyer. It is, therefore, worth taking a look at fallen small and mid-caps. For example, Cantourage shares gained more than 10% yesterday alone. Is there more to come for the cannabis stock? BlockchainK2 shares are also ripe for a price surge. The SaaS platform for financial service providers offers cost and efficiency benefits thanks to blockchain and AI. The sentiment for fintechs - look at PayPal - is currently brightening noticeably, and BlockchainK2 is a takeover candidate. The same could be said for Evotec, or is there a risk of a slide to EUR 4? In any case, the Company is not finding any peace.
Read
Commented by André Will-Laudien on September 2nd, 2024 | 07:30 CEST
DAX on a high, clear turnaround at Evotec and Saturn Oil + Gas, TUI and Lufthansa in a daily battle
The current stock market euphoria might seem out of place at first glance, given the geopolitical uncertainties, sluggish economic growth, and persistent inflation. However, it is important to remember: The stock market is looking 6 to 9 months ahead. The expectation is that inflation will weaken significantly, and the current interest rate level will fall considerably. In this environment of "steadily improving conditions", technology shares seem to be on the rise. Wars such as those in Ukraine or the Middle East may weigh on people's minds, but they boost the balance sheets of the defense industry. In this respect, there is little reason for pessimism, and the DAX at least reached new all-time highs at the end of August. It is worth taking a look at some of the lagging stocks.
Read
Commented by Fabian Lorenz on August 29th, 2024 | 07:00 CEST
Up to 200% upside potential! Evotec, Tui, and Almonty Industries shares!
Will Evotec's share price double or fall by 40%? Analyst opinions on the ailing biotech company differ widely. The management offers some encouragement, as insiders have been buying shares of Evotec. Almonty is currently performing strongly. The shares of the tungsten producer are at a yearly high. The half-year figures have been convincing, and analysts see around 200% upside potential. Has the share finally initiated its revaluation? By contrast, experts remain skeptical about Tui. Business is booming, but for how much longer?
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by Fabian Lorenz on August 8th, 2024 | 07:00 CEST
Siemens Energy tops, Evotec shocks, and what is causing the dynaCERT share to explode?
The Evotec share lost more than 35% yesterday. The share was already trading at a multi-year low before this drop. Investors were particularly shocked by the adjustment to the EBITDA forecast. Additionally, the biotech company indicated that it plans to downsize. This year, Siemens Energy has shown how quickly a difficult situation can be resolved. On the verge of bankruptcy at the end of 2023, it is back on track, although not thanks to renewable energies. In contrast, dynaCERT has yet to see its share price explode. A former Daimler manager will take the helm in the coming days and is expected to secure orders in Europe. Additionally, dynaCERT investors are waiting for VERRA certification.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read